Compare · LITS vs PFE
LITS vs PFE
Side-by-side comparison of Lite Strategy Inc. (LITS) and Pfizer Inc. (PFE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LITS and PFE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PFE is the larger of the two at $164.67B, about 6504.7x LITS ($25.3M).
- PFE has been more active in the news (16 items in the past 4 weeks vs 8 for LITS).
- PFE has more recent analyst coverage (25 ratings vs 0 for LITS).
- Company
- Lite Strategy Inc.
- Pfizer Inc.
- Price
- -
- -
- Market cap
- $25.3M
- $164.67B
- 1M return
- -
- -2.26%
- 1Y return
- -
- +11.47%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2003
- News (4w)
- 8
- 16
- Recent ratings
- 0
- 25
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest LITS
- Lite Strategy Reports Fiscal 2027 First Quarter Financial Results
- SEC Form 10-Q filed by Lite Strategy Inc.
- Lite Strategy Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities
- Director Glover Nicholas bought $12,550 worth of shares (2,000 units at $6.28) (SEC Form 4)
- SEC Form 4 filed by Lite Strategy Inc.
- SEC Form 4 filed by Lite Strategy Inc.
- SEC Form 4 filed by Lite Strategy Inc.
- SEC Form 4 filed by Lite Strategy Inc.
- Lite Strategy Marks 15 Years of Litecoin with Launch of "Proof of Time" Public Industry Archive
- SEC Form EFFECT filed by Lite Strategy Inc.
Latest PFE
- FDA Approval for DEFEROXAMINE MESYLATE issued to HOSPIRA
- SEC Form 13F-HR filed by Pfizer Inc.
- Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- FDA Approval for HYMPAVZI issued to PFIZER INC
- Pfizer downgraded by DZ Bank
- Pfizer Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Election Day Trading Splits the Benchmarks, With the Dow Lower and the Nasdaq Higher
- Chairman & CEO Bourla Albert was granted 20 units of Phantom Stock Units SSP (SEC Form 4)
- SEC Form 10-Q filed by Pfizer Inc.